Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Zimmer BioMet

What Are Wall Street Analysts' Target Price for Zimmer Biomet Stock?

As Zimmer Biomet has lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart

Zimmer Biomet’s Quarterly Earnings Preview: What You Need to Know

Zimmer Biomet is poised to report its first-quarter results in the near future, and Wall Street anticipates a measured, single-digit increase in earnings.

Barchart

How Is Zimmer Biomet Holdings’ Stock Performance Compared to Other Medical Devices Stocks?

Zimmer Biomet Holdings stock has lagged other medical device stocks over the past year, while analysts are neutral about its prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

With after-tax profits surging by close to 50% year-over-year, AstraZeneca emerges as a potential winner among healthcare names reporting earnings this month.

MarketBeat

Zimmer Biomet Stock: Is Wall Street Bullish or Bearish?

Zimmer Biomet has trailed the broader market over the past year, and it continues to face skeptical sentiment from analysts regarding its near- to medium-term growth outlook.

Barchart

EU Mulls Tariffs and Market Restrictions on US in Response to Greenland Threat

EU considers $108B in tariffs and market restrictions on the U.S. after Trump's Greenland threats, raising trade tensions.

International Business Times

Zimmer Biomet’s Q3 2025 Earnings: What to Expect

Zimmer Biomet is poised to report its fourth-quarter results in the near future, and Wall Street anticipates a measured, single-digit increase in earnings.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Zimmer Biomet Stock: Is ZBH Underperforming the Health Care Sector?

Despite Zimmer Biomet's underperformance relative to the broader healthcare sector over the past year, the stock is still viewed by analysts with moderate optimism.

Barchart

Zimmer Biomet Stock: Analyst Estimates & Ratings

Zimmer Biomet has significantly underperformed the broader market and other medical device stocks over the past year, yet analysts remain optimistic about the stock’s prospects.

Barchart

Zimmer Biomet Earnings Preview: What to Expect

Zimmer Biomet is set to post its third-quarter results next month, and analysts project a single-digit earnings rise.

Barchart

Is Zimmer Biomet Stock Underperforming the Dow?

Although Zimmer Biomet has lagged behind the Dow over the past year, analysts remain moderately optimistic about the stock’s prospects.

Barchart

Review launched over reports of delayed response to faulty knee replacement part

BBC’s File on 4 said patients were left immobile and addicted to painkillers due to issues with the joint replacement.

Evening Standard

Zimmer Biomet's $2.08 Billion Q2 Sales Ignite Orthopedic Surge, Boosts Guidance Outlook

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported second-quarter adjusted earnings of $2.07 per share, up 3% year over year, beating the Street estimates of $1.99.

Benzinga

Zimmer Biomet To Lead Orthopedic Robotics With Monogram's AI Tech

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) on Monday agreed to acquire Monogram Technologies Inc. (NASDAQ:MGRM) for an upfront payment of $4.04 per share, corresponding to an equity value of approximately $177 million and an enterprise value of approximately $168 million.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Zimmer Biomet Hits 34th 52-Week Low: Value Play or Value Trap?

Zimmer Biomet hit its 34th 52-week low on Tuesday. Its shares have decreased by over 20% in the past year. Trading at just 11.8x the 2025 EPS estimate, the maker of orthopedic medical devices looks cheap.

Barchart

Is Zimmer Biomet Stock Outperforming the S&P 500?

Zimmer Biomet has recently surged past the S&P 500 Index, with analysts maintaining a cautiously upbeat outlook on its growth potential.

Barchart

1 Stock to Buy ASAP to Cash in on the Pickleball Craze

As pickleball injuries rise, this medical device stock is perfectly positioned to cash in on the sport’s booming popularity.

Barchart

Are Wall Street Analysts Predicting Zimmer Biomet Stock Will Climb or Sink?

Despite trailing the broader market over the past year, Zimmer Biomet still holds a moderately favorable outlook among analysts.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

How Is Zimmer Biomet Holdings' Stock Performance Compared to Other Medical Device Stocks?

Zimmer Biomet Holdings has significantly underperformed other medical device stocks over the past year, yet analysts remain optimistic about the stock’s prospects.

MarketBeat

2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead

Medtronic (MDT) and Zimmer Biomet (ZBH) are emerging as serious contenders in robotic surgery, challenging Intuitive Surgical’s (ISRG) market dominance.

Barchart

Is Wall Street Bullish or Bearish on Zimmer Biomet Stock?

While Zimmer Biomet has lagged behind the broader market over the past year, analysts continue to hold a moderately positive view on the stock's prospects.

Fortune

Arnold Schwarzenegger, Zimmer Biomet’s first chief movement officer, wants older adults to stay active

The “Governator,” 77, is on a mission to spread the gospel of active aging.

Barchart

Here's What to Expect From Zimmer Biomet Holdings' Next Earnings Report

Zimmer Biomet Holdings is expected to release its third-quarter earnings later this month, and analysts expect a single-digit earnings growth.

Barchart

Zimmer Biomet Stock: Is ZBH Underperforming the Healthcare Sector?

Zimmer Biomet has underperformed the healthcare sector over the past year, yet analysts remain moderately bullish about the stock’s prospects.

Barchart

Are Wall Street Analysts Bullish on Zimmer Biomet Stock?

Despite Zimmer Biomet underperforming the broader market over the past year, analysts remain moderately bullish on the stock’s prospects.

1 2

People

Donald Trump

189,663 stories

Arnold Schwarzenegger

920 stories

Antonio Costa

161 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.